The annual EP Vantage Pharma & Biotech 2016 in Review report offers analysis and expert commentary on M&A deals venture financing, initial public offerings and FDA approvals in the pharma and biotech sector during 2016.
For the world’s drug makers 2016 was a year of two halves. Activity like deal-making and venture funding held up over the first two quarters, buoyed by the retreating bull market. However, as the US presidential election loomed ever closer, companies went into lockdown.
Key findings include:
